Intravenous ferric carboxymaltose is effective and safe for the treatment of iron deficiency anaemia in children affected by inflammatory bowel disease

2017 ◽  
Vol 49 (4) ◽  
pp. e261
Author(s):  
D. Knafelz ◽  
N. Acton ◽  
A. Angelakopoulou ◽  
S. Sider ◽  
S. Chadokufa ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Iron Deficiency ◽  
Bowel Disease ◽  
Iron Deficiency Anaemia ◽  
Ferric Carboxymaltose ◽  
Deficiency Anaemia ◽  
Inflammatory Bowel

scholarly journals DOP89 Effects of ferric derisomaltose and ferric carboxymaltose on hypophosphatemia in iron-deficiency anaemia due to Inflammatory Bowel Disease: A Phase IV randomised clinical trial

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S121-S121
Author(s):  
H Zoller ◽  
M Wolf ◽  
I Blumenstein ◽  
C Primas ◽  
S Lindgren ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Inflammatory Bowel Disease ◽  
Iron Deficiency ◽  
Bowel Disease ◽  
Iron Deficiency Anaemia ◽  
Randomised Clinical Trial ◽  
Ferric Carboxymaltose ◽  
Deficiency Anaemia ◽  
Fatigue Score ◽  
Inflammatory Bowel

Abstract Background Intravenous iron can correct iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD). Certain formulations are associated with hypophosphatemia, but this has not previously been investigated in a randomised clinical trial in IBD. The aim of this randomised, double-blind trial was to compare the risk of hypophosphatemia with ferric derisomaltose/iron isomaltoside 1000 (FDI) vs ferric carboxymaltose (FCM) in patients with IDA due to IBD. Methods Adults with IBD and IDA (haemoglobin [Hb] <13g/dL; s-ferritin ≤100ng/mL) who were unsuitable for oral iron treatment were recruited at outpatient clinics in 5 European countries. Patients were randomised 1:1 to FDI or FCM (1000mg at baseline and 500 or 1000mg at Week 5 based on weight and iron need at baseline). The primary endpoint was the incidence of hypophosphatemia (s-phosphate <2.0mg/dL) from baseline to Week 5. Additional endpoints included biomarkers of bone and mineral metabolism, Hb concentrations, fatigue score, and adverse events (AEs). Results Of 97 patients enrolled (mean age 42.1 years; 52.6% female; 39.2% Crohn’s disease; 60.8% ulcerative colitis), 48 received FDI and 49 FCM. The incidence of hypophosphatemia was significantly lower for FDI than FCM (8.3% vs. 51.0%; p<0.0001). After the first dose, biomarker responses (least squares mean change from baseline) were significantly less pronounced after FDI than FCM: s-phosphate decreased less with FDI than FCM, with a nadir at Week 1 (FDI, -0.49mg/dL; FCM, -1.33mg/dL; p<0.0001); urinary fractional excretion of phosphate increased less at Week 1 (FDI, 2.58%; FCM, 9.22%; p=0.0021); intact fibroblast growth factor 23 increased markedly over the first day only with FCM (FDI, -8.54pg/mL; FCM, 149.31pg/mL; p<0.0001); 1,25-dihydroxyvitamin D decreased less with FDI than FCM, with a nadir at Week 1 (FDI, -16.39pg/mL; FCM, -30.83pg/mL; p<0.0001); parathyroid hormone increased only in the FCM group, with a peak at Week 2 (FDI, -2.22pg/mL; FCM, 14.28pg/mL; p=0.011). Bone-specific alkaline phosphatase increased more with FCM than FDI at Week 2 (p=0.0025), with the difference persisting at Week 10 (p=0.0041). Hb increased in both groups and were comparable at all time points. Improvements from baseline in fatigue score were greater for FDI than FCM at Weeks 5 and 7 (both p<0.01). Incidence of AEs were comparable (FDI, 91.7%; FCM, 89.8%). Conclusion In IDA due to IBD, FDI resulted in significantly lower incidence of hypophosphatemia than FCM. FDI and FCM lead to similar increases in Hb concentration. In contrast to FDI, FCM treatment led to persistent changes in bone biomarkers, suggesting possible long-term adverse effects on bone health. ClinicalTrials.gov Identifier: NCT03466983. Supported by Pharmacosmos A/S (Holbæk, Denmark).

scholarly journals Interventions for treating iron deficiency anaemia in inflammatory bowel disease

2021 ◽  
Author(s):  
Morris Gordon ◽  
Vassiliki Sinopoulou ◽  
Zipporah Iheozor-Ejiofor ◽  
Tariq Iqbal ◽  
Patrick Allen ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Iron Deficiency ◽  
Bowel Disease ◽  
Iron Deficiency Anaemia ◽  
Deficiency Anaemia ◽  
Inflammatory Bowel

scholarly journals Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease

Nutrients ◽  
2018 ◽  
Vol 10 (1) ◽  
pp. 82 ◽  
Author(s):  
Ole Nielsen ◽  
Christoffer Soendergaard ◽  
Malene Vikner ◽  
Günter Weiss
Keyword(s):  
Inflammatory Bowel Disease ◽  
Iron Deficiency ◽  
Bowel Disease ◽  
Iron Deficiency Anaemia ◽  
Deficiency Anaemia ◽  
Rational Management ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document